Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene's Anti-PD-1 Approved in China for 4th and 5th Indications

publication date: Jun 23, 2021

BeiGene, a Beijing biotech, reported its anti-PD-1 antibody tislelizumab has been approved in China for two new indications, bringing the total to five. The new indications are first-line treatment for advanced non-squamous non-small cell lung cancer and conditional approval as a second-line therapy for hepatocellular carcinoma. In China, tislelizumab in now approved for lung, liver, bladder and lymphoma cancers. Earlier this year, BeiGene out-licensed global ex-China rights for tislelizumab to Novartis in a $2.2 billion agreement. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160) (NYSE: NVS)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.